Hematology

Study Finds Inhibitors Develop in Nonsevere Hemophilia A Earlier Than Previously Reported

October 30th 2020, 8:09pm

Article

Up until now, it was thought most patients with hemophilia A developed inhibitors in middle-age. A new study suggests it usually happens in the early teens.

Use of Triplet Therapy Rose in R/R MM as Deaths Declined, Study Finds

October 29th 2020, 9:45pm

Article

Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.

Patients With MM Living Longer, but Elderly Still Face Worse Survival

October 22nd 2020, 11:45am

Article

New data show that despite major improvements in survival rates in patients with multiple myeloma (MM), older patients with the malignancy have benefited less than younger patients.

Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse

October 21st 2020, 6:15pm

Article

Investigators may have found a minimally invasive way to predict which patients with multiple myeloma are about to experience a relapse.

CML Treatment Costs Continue to Rise Despite Availability of Generic Imatinib

October 13th 2020, 11:30am

Article

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib.

Colon Perforations in MM, While Rare, Linked With Corticosteroids

October 13th 2020, 10:30am

Article

A new report confirms earlier research that colon perforation in multiple myeloma is associated with corticosteroids, though the exact cause of the apparent link is not known.

MM Staging, Severe Anemia Linked With High Infection and Mortality Risk

October 7th 2020, 6:45pm

Article

Newly diagnosed patients with multiple myeloma (MM) face a high risk of infection. A new study helps elucidate key risk factors.

MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says

September 30th 2020, 5:00pm

Article

A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.

Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests

September 27th 2020, 3:30pm

Article

A subset of patients with multiple myeloma (MM) are not eligible for the most effective therapies, but a new study suggests clinicians may be inaccurately defining that subset.

Review Updates Mechanisms Underlying Proteasome Inhibitor Resistance in MM

September 23rd 2020, 7:15pm

Article

Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.